|
GOLPH3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.47929999863672E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.40889999958816E-08 |
| Normal-vs-Stage2 |
2.757900E-04 |
| Normal-vs-Stage3 |
1.83720000002108E-06 |
| Normal-vs-Stage4 |
2.63249999576942E-08 |
| Stage1-vs-Stage2 |
9.029400E-01 |
| Stage1-vs-Stage3 |
5.126800E-01 |
| Stage1-vs-Stage4 |
1.099220E-01 |
| Stage2-vs-Stage3 |
6.234400E-01 |
| Stage2-vs-Stage4 |
2.080600E-01 |
| Stage3-vs-Stage4 |
3.371000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.21749999473886E-08 |
| Normal-vs-AfricanAmerican |
4.560600E-03 |
| Normal-vs-Asian |
1.5877000000275E-06 |
| Caucasian-vs-AfricanAmerican |
5.669400E-01 |
| Caucasian-vs-Asian |
6.293200E-01 |
| AfricanAmerican-vs-Asian |
4.254800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.8583000000193E-07 |
| Normal-vs-Female |
6.86129999483143E-08 |
| Male-vs-Female |
7.215000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.06119999957011E-07 |
| Normal-vs-Age(41-60Yrs) |
9.20589999786614E-08 |
| Normal-vs-Age(61-80Yrs) |
6.13119999992584E-07 |
| Normal-vs-Age(81-100Yrs) |
6.064800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.314200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.170200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.833500E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.250600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.059900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.312100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.093170E-01 |
| Classical-VS-Follicular |
2.048100E-02 |
| Classical-VS-Other |
4.244800E-01 |
| Classical-VS-Normal |
4.07899999999017E-06 |
| Tall-VS-Follicular |
9.587400E-01 |
| Tall-VS-Other |
9.827200E-01 |
| Tall-VS-Normal |
1.71624999999453E-05 |
| Follicular-VS-Other |
9.954000E-01 |
| Follicular-VS-Normal |
3.77919999960952E-07 |
| Other-VS-Normal |
1.389790E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.08839999737975E-08 |
| Normal-vs-N1 |
3.89619999996427E-06 |
| N0-vs-N1 |
8.775600E-01 |
|
|
